Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
about
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Liver Illness and Psychiatric Patients.Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study.High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?Hepatitis C Cascade of Care Among Pregnant Women on Opioid Agonist Pharmacotherapy Attending a Comprehensive Prenatal Program.Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.HCV reinfection incidence among individuals treated for recent infection.Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program.Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review.Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care.Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?A Guide to the Economics of Hepatitis C Virus Cure in 2017Hepatitis C virus prevention and care for drug injectors: the French approachSafety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CEfficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
P2860
Q33853664-F09CBC08-AD45-4C88-953B-ADB0F763388DQ37587062-7D91992A-9BF5-4937-92E6-EF83091D58EAQ38377115-A43170B3-5D29-49CA-8DBF-6759FE90B15AQ38401928-F0E9C737-D541-4714-A7AD-E6187FD8253FQ38623266-2BBBB35D-C909-4B2A-878E-BB4E2668B0A8Q38635796-FB4B3AE5-AE5B-469D-99BA-4C76B32E3537Q38661825-17C34AB5-98C9-41F6-A8BC-D480F3DBBF10Q38746105-3365C363-9CDC-4E9D-9BC9-12E28E29DD6CQ40082158-147140DC-18AC-4029-97FE-CDAF99FD959AQ40092669-48A66AF6-C5CF-4550-A63F-9604749063BCQ40126429-33CC0253-52C5-48EC-B1A3-F0719A2B7548Q40239514-18319646-D85D-4E37-9207-393887D5DC09Q40393982-91238990-550B-499A-BAE6-114F62A944BDQ40483611-36498E74-8829-4AC2-9D75-FDC284B5D246Q40565822-68AF8667-342D-42FF-9038-81281CE95B65Q40565832-2F8B6D14-24A1-4FD1-920A-9B2F1F945041Q45324640-51D8E79F-157F-41A1-B929-9317681ABD56Q46084794-77591966-EF2C-4B86-A5E6-BCD62F0A9751Q47274505-C39F90B0-F054-4E64-98FD-FCA724C0AB82Q47562656-A5C94226-9FE3-49EC-BA91-E6298FAC7879Q49823266-DB2D2EF8-BBAA-4C71-85EF-846209617483Q49953662-1B89C10B-2CA5-4FF7-940D-3DADB8070CD5Q52592715-30B7AA33-F2F9-4B62-AB0D-BEC9818CB782Q52597000-33BAAFE9-0752-48E0-BA12-AE495C16D376Q52686909-CDACA87F-838A-44A8-91EF-0C2DA7C7EA28Q52699078-B327EB53-CA5A-4197-A843-675700FC2E73Q54216905-DA4C7EBA-F60B-4781-BD60-44B2B264B3A6Q55065074-AED75B76-5587-4936-98E9-DA85D38F64E5Q55187199-CFEC286E-FEAE-46DA-81E9-9A83F8021B42Q55425578-EBCB2D1E-C9DD-4621-A29C-7339EF7FA2D7Q56654943-EE9DADF1-E89A-4314-8916-0B048DBC8FE1Q57144432-7DCEE21D-92DF-4F76-8B0F-6A1F1E8275A3Q58763037-2511D818-94BD-4714-831F-264DE438F2A6Q58788714-DCACF5D0-4F63-46A8-98A6-24A34098B349Q59133541-2F49B8B1-F5A1-4777-99BB-C53BC395D4B4
P2860
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Elbasvir-Grazoprevir to Treat ...... t Therapy: A Randomized Trial.
@en
type
label
Elbasvir-Grazoprevir to Treat ...... t Therapy: A Randomized Trial.
@en
prefLabel
Elbasvir-Grazoprevir to Treat ...... t Therapy: A Randomized Trial.
@en
P2093
P356
P1476
Elbasvir-Grazoprevir to Treat ...... t Therapy: A Randomized Trial.
@en
P2093
Alain H Litwin
Anita Y M Howe
Bach-Yen Nguyen
Brian Conway
C-EDGE CO-STAR Study Group
Cheng-Yuan Peng
David C Nickle
Edward J Gane
Eliav Barr
Erluo Chen
P304
P356
10.7326/M16-0816
P407
P577
2016-08-09T00:00:00Z